These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 20220001

  • 1. Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation.
    Ortega Z, Díaz-Hernández M, Maynard CJ, Hernández F, Dantuma NP, Lucas JJ.
    J Neurosci; 2010 Mar 10; 30(10):3675-88. PubMed ID: 20220001
    [Abstract] [Full Text] [Related]

  • 2. Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment.
    Maynard CJ, Böttcher C, Ortega Z, Smith R, Florea BI, Díaz-Hernández M, Brundin P, Overkleeft HS, Li JY, Lucas JJ, Dantuma NP.
    Proc Natl Acad Sci U S A; 2009 Aug 18; 106(33):13986-91. PubMed ID: 19666572
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons.
    Tydlacka S, Wang CE, Wang X, Li S, Li XJ.
    J Neurosci; 2008 Dec 03; 28(49):13285-95. PubMed ID: 19052220
    [Abstract] [Full Text] [Related]

  • 5. Global changes to the ubiquitin system in Huntington's disease.
    Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR.
    Nature; 2007 Aug 09; 448(7154):704-8. PubMed ID: 17687326
    [Abstract] [Full Text] [Related]

  • 6. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease.
    Bett JS, Cook C, Petrucelli L, Bates GP.
    PLoS One; 2009 Aug 09; 4(4):e5128. PubMed ID: 19352500
    [Abstract] [Full Text] [Related]

  • 7. Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease.
    Mitra S, Tsvetkov AS, Finkbeiner S.
    J Biol Chem; 2009 Feb 13; 284(7):4398-403. PubMed ID: 19074152
    [Abstract] [Full Text] [Related]

  • 8. Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments.
    Li X, Wang CE, Huang S, Xu X, Li XJ, Li H, Li S.
    Hum Mol Genet; 2010 Jun 15; 19(12):2445-55. PubMed ID: 20354076
    [Abstract] [Full Text] [Related]

  • 9. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
    Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY.
    Hum Mol Genet; 2005 Mar 01; 14(5):679-91. PubMed ID: 15661755
    [Abstract] [Full Text] [Related]

  • 10. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice.
    Wang J, Wang CE, Orr A, Tydlacka S, Li SH, Li XJ.
    J Cell Biol; 2008 Mar 24; 180(6):1177-89. PubMed ID: 18362179
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain.
    Díaz-Hernández M, Valera AG, Morán MA, Gómez-Ramos P, Alvarez-Castelao B, Castaño JG, Hernández F, Lucas JJ.
    J Neurochem; 2006 Sep 24; 98(5):1585-96. PubMed ID: 16787406
    [Abstract] [Full Text] [Related]

  • 12. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
    Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP.
    Hum Mol Genet; 2006 Jan 01; 15(1):33-44. PubMed ID: 16311253
    [Abstract] [Full Text] [Related]

  • 13. Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin.
    Valera AG, Díaz-Hernández M, Hernández F, Lucas JJ.
    Brain Res Bull; 2007 Apr 30; 72(2-3):121-3. PubMed ID: 17352935
    [Abstract] [Full Text] [Related]

  • 14. Modest proteasomal inhibition by aberrant ubiquitin exacerbates aggregate formation in a Huntington disease mouse model.
    de Pril R, Hobo B, van Tijn P, Roos RA, van Leeuwen FW, Fischer DF.
    Mol Cell Neurosci; 2010 Mar 30; 43(3):281-6. PubMed ID: 20005957
    [Abstract] [Full Text] [Related]

  • 15. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation.
    Bennett EJ, Bence NF, Jayakumar R, Kopito RR.
    Mol Cell; 2005 Feb 04; 17(3):351-65. PubMed ID: 15694337
    [Abstract] [Full Text] [Related]

  • 16. The neuronal ubiquitin-proteasome system: murine models and their neurological phenotype.
    van Tijn P, Hol EM, van Leeuwen FW, Fischer DF.
    Prog Neurobiol; 2008 Jun 04; 85(2):176-93. PubMed ID: 18448229
    [Abstract] [Full Text] [Related]

  • 17. Is the ubiquitin-proteasome system impaired in Huntington's disease?
    Ortega Z, Díaz-Hernández M, Lucas JJ.
    Cell Mol Life Sci; 2007 Sep 04; 64(17):2245-57. PubMed ID: 17604996
    [Abstract] [Full Text] [Related]

  • 18. Temporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington's disease mutation.
    Gong B, Kielar C, Morton AJ.
    PLoS One; 2012 Sep 04; 7(7):e41450. PubMed ID: 22848498
    [Abstract] [Full Text] [Related]

  • 19. α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease.
    Tomás-Zapico C, Díez-Zaera M, Ferrer I, Gómez-Ramos P, Morán MA, Miras-Portugal MT, Díaz-Hernández M, Lucas JJ.
    Hum Mol Genet; 2012 Feb 01; 21(3):495-510. PubMed ID: 22045698
    [Abstract] [Full Text] [Related]

  • 20. Protein turnover and inclusion body formation.
    Mitra S, Tsvetkov AS, Finkbeiner S.
    Autophagy; 2009 Oct 01; 5(7):1037-8. PubMed ID: 19838079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.